Detail Information of Post-Translational Modifications

General Information of Drug Transporter (DT)
DT ID	DTD0133 Transporter Info
Gene Name	SLC1A5
Transporter Name	Alanine/serine/cysteine/threonine transporter 2
Gene ID	6510
UniProt ID	Q15758

Post-Translational Modification of This DT
Overview of SLC1A5 Modification Sites with Functional and Structural Information
Sequence	M V A D P P R D S K G L A A A E P T A N G G L A L A S I E D Q G A A A G G Y C G S R D Q V R R C L R A N L L V L L T V V A V V A G V A L G L G V S G A G G A L A L G P E R L S A F V F P G E L L L R L L R M I I L P L V V C S L I G G A A S L D P G A L G R L G A W A L L F F L V T T L L A S A L G V G L A L A L Q P G A A S A A I N A S V G A A G S A E N A P S K E V L D S F L D L A R N I F P S N L V S A A F R S Y S T T Y E E R N I T G T R V K V P V G Q E V E G M N I L G L V V F A I V F G V A L R K L G P E G E L L I R F F N S F N E A T M V L V S W I M W Y A P V G I M F L V A G K I V E M E D V G L L F A R L G K Y I L C C L L G H A I H G L L V L P L I Y F L F T R K N P Y R F L W G I V T P L A T A F G T S S S S A T L P L M M K C V E E N N G V A K H I S R F I L P I G A T V N M D G A A L F Q C V A A V F I A Q L S Q Q S L D F V K I I T I L V T A T A S S V G A A G I P A G G V L T L A I I L E A V N L P V D H I S L I L A V D W L V D R S C T V L N V E G D A L G A G L L Q N Y V D R T E S R S T E P E L I Q V K S E L P L D P L P V P T E E G N P L L K H Y R G P A G D A T V A S E K E S V M
PTM type	X-Acetylation X-Monomethylation X-N-glycosylation X-Oxidation X-Phosphorylation X-S-nitrosylation X-S-palmitoylation X-Sulfoxidation X-Ubiquitination X: Amino Acid

Acetylation
Lysine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[1]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	522
Experimental Method	Co-Immunoprecipitation
Detailed Description	Acetylation at SLC1A5 Lysine 522 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Lysine	Modified Location	537
Experimental Method	Co-Immunoprecipitation
Detailed Description	Acetylation at SLC1A5 Lysine 537 has the potential to affect its expression or activity.
Methionine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[3] , [4]
Role of PTM	Potential impacts
Modified Residue	Methionine	Modified Location	1
Experimental Method	Co-Immunoprecipitation
Detailed Description	Acetylation at SLC1A5 Methionine 1 has the potential to affect its expression or activity.
Monomethylation
Arginine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Arginine	Modified Location	525
Experimental Method	Co-Immunoprecipitation
Detailed Description	Monomethylation at SLC1A5 Arginine 525 has the potential to affect its expression or activity.
N-glycosylation
Asparagine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Impairing the trafficking to the membrane of SLC1A5			[2]
Role of PTM	Trafficking to Plasma Membrane
Affected Drug/Substrate	Glutamate	Results for Drug	no effect in the transport function
Modified Residue	Asparagine	Modified Location	163
Modified State	Asparagine to Glutamine mutation
Experimental Method	Co-Immunoprecipitation
Detailed Description	Removal of the Glycosylation at SLC1A5 Asparagine 163 (i.e. Asparagine to Glutamine mutation) have been reported to impaire its trafficking to the membrane.
PTM Phenomenon 2	Impairing the trafficking to the membrane of SLC1A5			[2]
Role of PTM	Trafficking to Plasma Membrane
Affected Drug/Substrate	Glutamate	Results for Drug	no effect in the transport function
Modified Residue	Asparagine	Modified Location	212
Modified State	Asparagine to Glutamine mutation
Experimental Method	Co-Immunoprecipitation
Detailed Description	Removal of the Glycosylation at SLC1A5 Asparagine 212 (i.e. Asparagine to Glutamine mutation) have been reported to impaire its trafficking to the membrane.
Oxidation
Cystine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[5]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	467
Experimental Method	Co-Immunoprecipitation
Detailed Description	Oxidation at SLC1A5 Cystine 467 has the potential to affect its expression or activity.
Phosphorylation
Serine	10 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Serine	Modified Location	9
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Serine 9 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Serine	Modified Location	27
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Serine 27 has the potential to affect its expression or activity.
PTM Phenomenon 3	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Serine	Modified Location	183
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Serine 183 has the potential to affect its expression or activity.
PTM Phenomenon 4	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Serine	Modified Location	194
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Serine 194 has the potential to affect its expression or activity.
PTM Phenomenon 5	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Serine	Modified Location	198
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Serine 198 has the potential to affect its expression or activity.
PTM Phenomenon 6	Have the potential to influence SLC1A5			[6] , [7]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	491
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Serine 491 has the potential to affect its expression or activity.
PTM Phenomenon 7	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Serine	Modified Location	493
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Serine 493 has the potential to affect its expression or activity.
PTM Phenomenon 8	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Serine	Modified Location	503
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Serine 503 has the potential to affect its expression or activity.
PTM Phenomenon 9	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Serine	Modified Location	535
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Serine 535 has the potential to affect its expression or activity.
PTM Phenomenon 10	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Serine	Modified Location	539
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Serine 539 has the potential to affect its expression or activity.
Threonine	7 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[8] , [9]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	18
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Threonine 18 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC1A5			[10]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	206
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Threonine 206 has the potential to affect its expression or activity.
PTM Phenomenon 3	Have the potential to influence SLC1A5			[10]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	214
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Threonine 214 has the potential to affect its expression or activity.
PTM Phenomenon 4	Have the potential to influence SLC1A5			[7] , [11]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	489
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Threonine 489 has the potential to affect its expression or activity.
PTM Phenomenon 5	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Threonine	Modified Location	494
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Threonine 494 has the potential to affect its expression or activity.
PTM Phenomenon 6	Have the potential to influence SLC1A5			[12] , [13]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	514
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Threonine 514 has the potential to affect its expression or activity.
PTM Phenomenon 7	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Threonine	Modified Location	532
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Threonine 532 has the potential to affect its expression or activity.
Tyrosine	3 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Tyrosine	Modified Location	38
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Tyrosine 38 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC1A5			[10]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	204
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Tyrosine 204 has the potential to affect its expression or activity.
PTM Phenomenon 3	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Tyrosine	Modified Location	524
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC1A5 Tyrosine 524 has the potential to affect its expression or activity.
S-nitrosylation
Cystine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[14]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	39
Experimental Method	Co-Immunoprecipitation
Detailed Description	S-nitrosylation (-SNO) at SLC1A5 Cystine 39 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC1A5			[14] , [15]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	467
Experimental Method	Co-Immunoprecipitation
Detailed Description	S-nitrosylation (-SNO) at SLC1A5 Cystine 467 has the potential to affect its expression or activity.
S-palmitoylation
Cystine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[16] , [17]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	39
Experimental Method	Co-Immunoprecipitation
Detailed Description	S-palmitoylation at SLC1A5 Cystine 39 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC1A5			[16]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	467
Experimental Method	Co-Immunoprecipitation
Detailed Description	S-palmitoylation at SLC1A5 Cystine 467 has the potential to affect its expression or activity.
Sulfoxidation
Methionine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[18]
Role of PTM	Potential impacts
Modified Residue	Methionine	Modified Location	541
Experimental Method	Co-Immunoprecipitation
Detailed Description	Sulfoxidation at SLC1A5 Methionine 541 has the potential to affect its expression or activity.
Ubiquitination
Alanine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[19]
Role of PTM	Potential impacts
Modified Residue	Alanine	Modified Location	300
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC1A5 Alanine 300 has the potential to affect its expression or activity.
Asparticacid	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[19]
Role of PTM	Potential impacts
Modified Residue	Asparticacid	Modified Location	294
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC1A5 Asparticacid 294 has the potential to affect its expression or activity.
Lysine	7 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Decreasing cell surface expression of SLC1A5			[20]
Role of PTM	Surface Expression Modulation
Modified Residue	Lysine	Modified Location	10
Studied Phenotype	Hepatoblastoma [ICD11: 2C12.01]
Experimental Material(s)	Human hepatoblastoma (HepG2.2.15) cells
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC1A5 Lysine 10 have been reported to decrease its cell surface expression.
PTM Phenomenon 2	Decreasing cell surface expression of SLC1A5			[20]
Role of PTM	Surface Expression Modulation
Modified Residue	Lysine	Modified Location	522
Studied Phenotype	Hepatoblastoma [ICD11: 2C12.01]
Experimental Material(s)	Human hepatoblastoma (HepG2.2.15) cells
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC1A5 Lysine 522 have been reported to decrease its cell surface expression.
PTM Phenomenon 3	Decreasing cell surface expression of SLC1A5			[20]
Role of PTM	Surface Expression Modulation
Modified Residue	Lysine	Modified Location	537
Studied Phenotype	Hepatoblastoma [ICD11: 2C12.01]
Experimental Material(s)	Human hepatoblastoma (HepG2.2.15) cells
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC1A5 Lysine 537 have been reported to decrease its cell surface expression.
PTM Phenomenon 4	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Lysine	Modified Location	178
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC1A5 Lysine 178 has the potential to affect its expression or activity.
PTM Phenomenon 5	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Lysine	Modified Location	247
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC1A5 Lysine 247 has the potential to affect its expression or activity.
PTM Phenomenon 6	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Lysine	Modified Location	372
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC1A5 Lysine 372 has the potential to affect its expression or activity.
PTM Phenomenon 7	Have the potential to influence SLC1A5			[2]
Role of PTM	Potential impacts
Affected Drug/Substrate	Glutamate	Results for Drug	Affecting the inward transport of glutamate
Modified Residue	Lysine	Modified Location	502
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC1A5 Lysine 502 has the potential to affect its expression or activity.
Methionine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[19]
Role of PTM	Potential impacts
Modified Residue	Methionine	Modified Location	274
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC1A5 Methionine 274 has the potential to affect its expression or activity.
Valine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC1A5			[19]
Role of PTM	Potential impacts
Modified Residue	Valine	Modified Location	320
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC1A5 Valine 320 has the potential to affect its expression or activity.

References
1	Lysine Acetylation and Succinylation in HeLa Cells and their Essential Roles in Response to UV-induced Stress. Sci Rep. 2016 Jul 25;6:30212.
2	The Human SLC1A5 (ASCT2) Amino Acid Transporter: From Function to Structure and Role in Cell Biology. Front Cell Dev Biol. 2018 Sep 4;6:96.
3	Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem. 2009 Jun 1;81(11):4493-501.
4	N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB. Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12449-54.
5	A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during Aging. Cell. 2020 Mar 5;180(5):968-983.e24.
6	Capillary Zone Electrophoresis-Tandem Mass Spectrometry for Large-Scale Phosphoproteomics with the Production of over 11,000 Phosphopeptides from the Colon Carcinoma HCT116 Cell Line. Anal Chem. 2019 Feb 5;91(3):2201-2208.
7	Defeating Major Contaminants in Fe3+- Immobilized Metal Ion Affinity Chromatography (IMAC) Phosphopeptide Enrichment. Mol Cell Proteomics. 2018 May;17(5):1028-1034.
8	An integrated strategy for highly sensitive phosphoproteome analysis from low micrograms of protein samples. Analyst. 2018 Jul 23;143(15):3693-3701.
9	Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1. EMBO J. 2015 Nov 12;34(22):2840-61.
10	Improved Method for Determining Absolute Phosphorylation Stoichiometry Using Bayesian Statistics and Isobaric Labeling. J Proteome Res. 2017 Nov 3;16(11):4217-4226.
11	Tip-Based Fractionation of Batch-Enriched Phosphopeptides Facilitates Easy and Robust Phosphoproteome Analysis. J Proteome Res. 2018 Jan 5;17(1):46-54.
12	Phosphoproteomics to Characterize Host Response During Influenza A Virus Infection of Human Macrophages. Mol Cell Proteomics. 2016 Oct;15(10):3203-3219.
13	Temporal proteomic analysis of HIV infection reveals remodelling of the host phosphoproteome by lentiviral Vif variants. Elife. 2016 Sep 30;5:e18296.
14	Proteome-wide detection of S-nitrosylation targets and motifs using bioorthogonal cleavable-linker-based enrichment and switch technique. Nat Commun. 2019 May 16;10(1):2195.
15	Dual Labeling Biotin Switch Assay to Reduce Bias Derived From Different Cysteine Subpopulations: A Method to Maximize S-Nitrosylation Detection. Circ Res. 2015 Oct 23;117(10):846-57.
16	Selective Enrichment and Direct Analysis of Protein S-Palmitoylation Sites. J Proteome Res. 2018 May 4;17(5):1907-1922.
17	Proteome scale characterization of human S-acylated proteins in lipid raft-enriched and non-raft membranes. Mol Cell Proteomics. 2010 Jan;9(1):54-70.
18	Redox proteomics of protein-bound methionine oxidation. Mol Cell Proteomics. 2011 May;10(5):M110.006866.
19	A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol Cell Proteomics. 2011 Oct;10(10):M111.013284.
20	Global analysis of HBV-mediated host proteome and ubiquitylome change in HepG2.2.15 human hepatoblastoma cell line. Cell Biosci. 2021 Apr 17;11(1):75.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.

Detail Information of Post-Translational Modifications

Visitor Map

Correspondence